EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Validation of Gazelle Microchip Electrophoresis for Premarital Hemoglobinopathy Screening in Türkiye

Duran Canatan iD, Serpil Delibaş, Emel Altunsoy, Elif Gözde Gökkaya, Sultan Aydın, Defne Ay Tuncel, Rucha Natu, Priyaleela Thota, Umut A Gurkan iD

eJHaem · 2026-06 · 7 (3)

DOI: 10.1002/jha2.70310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eJHaem, online erschienen am 06.06.2026. Verfasst von Duran Canatan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Antalya Bilim University Antalya Türkiye. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hemoglobinopathies, the most prevalent recessive monogenic disorders globally, encompass thalassemia syndromes and structural hemoglobin variants, affecting approximately 5% of the world's population as carriers, with around 315,000 affected births annually. These conditions are especially common in regions including the Mediterranean Basin, parts of Africa, the Middle East, India, and Southeast Asia. Traditional screeningcomplete blood count (CBC), high‐performance liquid chromatography (HPLC), and capillary electrophoresis (CE)followed by molecular genetic confirmation, requires skilled personnel and advanced facilities, which are often scarce in high‐prevalence, low‐resource areas, rendering them inaccessible to many. Gazelle, a novel, point‐of‐care (POC) microchip‐based cellulose acetate electrophoresis platform, promises an affordable and accessible alternative for detecting common hemoglobin variants.

Methods

This study evaluates Gazelle's performance against HPLC for premarital screening in Antalya, Türkiye, enrolling 616 participants: 516 for screening and 100 known carriers (81 beta‐thalassemia, 19 sickle cell) as controls. Participants underwent CBC, HPLC, and Gazelle testing, with positive results confirmed by beta‐gene sequencing.

Results

Among the 516 screened (55.1% women, 44.9% men, average age 32.75 ± 11.25 years), 16 traits (3.2%) were identified, including 14 beta‐thalassemia, one HbS, and one HbD. Statistical analysis confirmed 100% diagnostic agreement between Gazelle and HPLC.

Conclusion

Gazelle's advantages include rapid results, digital storage, Wi‐Fi connectivity, portability, and printed reports, which make it a transformative tool for identifying hemoglobin variants like HbA, HbS, HbF, and HbA2, and accurately detecting β‐thalassemia carriers in resource‐limited settings. Future efforts will focus on analytically validating Gazelle through evaluations of sample stability, operator variability, and repeatability/reproducibility in clinical settings to strengthen its positioning as a screening platform. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission

Schlagwörter

Stichwörter der Autor:innen

anemiabeta‐thalassemiahemoglobin variantshemoglobinopathiespoint‐of‐care

Autor:innen und Institutionen

  • Antalya Bilim University Antalya Türkiye.
  • Hemoglobinopathy Diagnosis Thalassemia Center of Mediterranean Blood Diseases Foundation Antalya Türkiye.
  • Antalya Genetic Diseases Assessment Center Antalya Türkiye.
  • Thalassemia Center, Antalya Education and Research Hospital Health Sciences University Antalya Türkiye.
  • Pediatric Hematology Oncology Clinic, Adana City Training and Research Hospital Health Sciences University Adana Türkiye.
  • Department of Mechanical and Aerospace Engineering Case Western Reserve University Cleveland Ohio USA.

ORCID-Profile: Duran Canatan, Umut A Gurkan

Förderung

  • National Institutes of Health

Zitieren

APA

Canatan, D., Delibaş, S., Altunsoy, E., Gökkaya, E. G., Aydın, S., Tuncel, D. A., Natu, R., Thota, P., & Gurkan, U. A. (2026). Validation of Gazelle Microchip Electrophoresis for Premarital Hemoglobinopathy Screening in Türkiye. eJHaem, 7(3). https://doi.org/10.1002/jha2.70310

Vancouver

Canatan D, Delibaş S, Altunsoy E, Gökkaya EG, Aydın S, Tuncel DA, et al. Validation of Gazelle Microchip Electrophoresis for Premarital Hemoglobinopathy Screening in Türkiye. eJHaem. 2026;7(3). doi:10.1002/jha2.70310

BibTeX
@article{Canatan2026,
  author = {Canatan, Duran and Delibaş, Serpil and Altunsoy, Emel and Gökkaya, Elif Gözde and Aydın, Sultan and Tuncel, Defne Ay and Natu, Rucha and Thota, Priyaleela and Gurkan, Umut A},
  title = {Validation of Gazelle Microchip Electrophoresis for Premarital Hemoglobinopathy Screening in Türkiye},
  journal = {eJHaem},
  year = {2026},
  volume = {7},
  number = {3},
  doi = {10.1002/jha2.70310}
}
Kostenlos starten →